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ABSTRACT
Background. In the tumor microenvironment, factors
inhibiting the targeting of cancer cells by activated T cells
have recently been noted. B7-H3 belongs to the B7 super-
family of immune regulatory ligands and plays an important
role in the adaptive immune response of co-inhibitory/sti-
mulatory factors in regulating T cells. However, the degree
to which B7-H3 directly affects tumor immune evasion
mechanisms remains unclear, particularly in patients with
breast cancer. Regulatory T cells (Tregs) are known as a key
player in the inhibition of immune mechanisms. The present
study demonstrated that expression of B7-H3 on tumor cells
and the number of Tregs in the tumor microenvironment
independently affected prognosis in breast cancer patients.
Methods. We immunohistochemically investigated the
presence of B7-H3 and forkhead box P3 (Foxp3)-positive
Tregs in pathological specimens from 90 patients with
breast cancer.
Results. Positive B7-H3 expression was associated with
shorter recurrence-free survival (RFS) (p = 0.014). A
higher percentage of Foxp3-positive cells also correlated
with shorter RFS (p = 0.039). Multivariate analysis
showed B7-H3 as an independent factor on RFS. Foxp3
expression in tumor-infiltrating lymphocytes (TILs)
correlated significantly with larger tumor size ([2 cm),
expression of human epidermal growth factor receptor 2
(HER2), and higher nuclear grade (p = 0.003, p \ 0.001,
p = 0.001, respectively). No correlation was identified
between expression of B7-H3 and the percentage of Foxp3-
positive TILs.
Conclusions. B7-H3 and Foxp3 can be regarded as
markers of poor prognosis in breast cancer. These expres-
sions were not correlated, suggesting that B7-H3
expression plays an independent role in tumor immune
evasion, regardless of Tregs.
Breast cancer is the fifth leading cause of cancer deaths
among women in Japan. In attempts to control breast
cancer, clarification of the tumor microenvironment will
prove important. In this environment, the present study
focused on interactions between tumor and immune
effector cells. Several mechanisms have been suggested to
result in the immune defects seen in breast cancer patients,
such as a lower number of blood lymphocytes 1,2 and
elevated levels of T-regulatory lymphocytes in breast
cancer.3 B7-H3 belongs to the B7 family as a known co-
inhibitory ligand.4 The receptor for B7-H3 has not been
clearly identified, so the mechanisms underlying the effects
of B7-H3 on the immune system remain unclear, particu-
larly in terms of targeting T cells for suppression.
Expression of B7-H3 protein has been detected in several
tumor cell lines along with human malignancies of the
lymphoma,1 ovary,5 lung,6 stomach,7 prostate,8 and pan-
creas,9,10 clear cell renal carcinoma,11 and colorectal
carcinoma.12 It was reported that B7-H3 is a type1
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transmembrane protein.13,14 Two possible receptors have
been postulated for B7-H3 on T cells, one that gives rise to
activating signals,14 whereas the other exerts inhibitory
signals.15 In EL-4 lymphoma, Sun et al. 1 showed that B7-
H3 displayed antitumor activity, as intratumoral injection
of a B7-H3 expression plasmid led to complete regression
of 50 % of lymphoma and otherwise significantly slowed
tumor growth. B7-H3 mediated antitumor immunity was
reported to mediate by CD8? T cells and natural killer
(NK) cells instead of CD4? T cells. In contrast, other
groups reported that treatment by intratumoral injection of
an adenovirus-expressing mouse B7-H3 (Ad-B7-H3-GFP)
resulted in a reduction of tumor size compared with control
animals in the orthotropic murine colon cancer model.16 As
a result, B7-H3 appears likely to exert both stimulatory and
inhibitory immunological functions. Recently, B7-H3
messenger RNA (mRNA) and protein expression in breast
cancer was reported.17 B7-H3 expression was found to
correlate with the size of the primary tumor and lympho-
vascular invasion, as evaluated by the American Joint
Committee on Cancer (AJCC) stage of breast cancer. B7-
H3 also appears to be strongly expressed in breast cancer
cells, with expression related to the progression of primary
breast cancer to axillary lymph nodes.17
Regulatory T cells (Tregs) have been found to be
involved in the maintenance of immune tolerance, both
preventing autoimmune disease and curtailing antitumor
immune response. These cells can suppress the actions of
cytotoxic lymphocytes. Forkhead box P3 (Foxp3) is a
member of the forkhead/winged-helix family of transcrip-
tion regulators involved in regulating immune system
development and function.18 This gene plays a crucial role
in the generation of CD4?CD25? Tregs, and the loss of
Foxp3 function leads to a lack of Tregs, resulting in lethal
autoaggressive lymphoproliferation, whereas overexpres-
sion of Foxp3 results in severe immunodeficiency.19 High
levels of Tregs have been reported in the peripheral
blood,20–22 lymph nodes,23,24 tumor specimens,22,25 and
ascites 21 of patients with different types of cancer. The
prognostic importance of Foxp3 expression in patients with
breast cancer has been investigated. Foxp3 expression in
breast tumor has been associated with lower probability of
overall survival (OS), with increasing intensity of Foxp3
immunostaining.26 Foxp3 was also a strong prognostic
factor for distant metastasis-free survival, but not local
recurrence risk.26 The clinical significance of tumor infil-
trating Foxp3-positive Tregs has been assessed in breast
cancer patients with long-term follow-up. Bates et al. 27
indicated that high numbers of Foxp3-positive Tregs rep-
resent an important marker for the identification of breast
cancer patients at risk of late relapse. They also found that
the number of tumor-associated Tregs was a significant
prognostic parameter for both invasive and non-invasive
breast cancers that can be assessed in routinely fixed tissues
by immunohistochemistry (IHC) to detect Foxp3-positive
Tregs.27
The purpose of this study was to correlate the expression
of B7-H3 and the number of Tregs in primary tumors of
breast cancer. We focused on the relationship of both
expressions of B7-H3 on tumor cells and infiltration of
Tregs.
MATERIALS AND METHODS
Patients and Tissue Samples
Participants comprised 90 patients with breast cancer
who underwent surgery in the Department of Digestive
Surgery and Surgical Oncology at Yamaguchi University
Graduate School of Medicine (Yamaguchi, Japan) between
April 2003 and March 2007.
Primary tumor specimens were collected from 90
patients with invasive ductal carcinoma who underwent
surgery (breast-conserving surgery or total mastectomy)
plus sentinel lymph node and/or axillary lymph node dis-
section. No patients had received any treatment before
surgery. Written informed consent was obtained from all
patients and the study protocol was approved by the
Institutional Review Board for Human Use at Yamaguchi
University School of Medicine.
Fifty-four patients (60 %) underwent breast-conserving
surgery plus locoregional radiotherapy, and 36 patients
(40 %) underwent modified radical mastectomy. Clinical
examinations were performed every 3 or 6 months during
the first 5 years according to the prognostic risk of the
patient, and annually thereafter. Mammograms were per-
formed annually. Eighty-eight patients received adjuvant
therapy, consisting of chemotherapy alone in 15 cases,
hormone therapy alone in 29 cases, and both in 44 cases.
No human epidermal growth factor receptor 2 (HER2)-
positive patients were treated with anti-HER2 therapy as an
adjuvant therapy. The histological type and number of
positive axillary nodes were established at the time of
surgery. The malignancy of infiltrating carcinomas was
scored using the histoprognostic system described by
Bloom and Richardson.28
Estrogen receptor (ER) and progesterone receptor (PgR)
statuses were determined using IHC. A tumor was con-
sidered HER2-positive from IHC with a score of 3? or a
score of 2? with uniform intense membrane staining of
[10 % of invasive tumor cells. Median follow-up was
67 months (range 7.8–90.5 months). Thirteen patients
developed metastases. Recurrence-free survival (RFS) was
defined as the time between initial diagnosis and first
recurrence.
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Immunohistochemistry
Sections of 5 lm thickness were cut from paraffin-
embedded tissue blocks, mounted on silanated slides, and
subsequently dewaxed and rehydrated using xylene and
graded alcohol washes. Antigen retrieval was carried out
by microwaving in DAKO Target Retrieval Solution (pH 9;
Dako, Glostrup, Denmark). Endogenous peroxidase was
blocked for 15 min with 0.3 % hydrogen peroxide (Wako
Pure Chemical Industries, Tokyo, Japan) in phosphate-
buffered saline (PBS) [Oxoid, Hampshire, UK] containing
0.1 % sodium azide. After two washes in PBS, sections
were blocked with serum-free protein blocker (Dako) for
10 min, followed by the addition of a primary antibody.
The following primary antibodies were used in accordance
with the instructions from the manufacturer: B7-H3 anti-
body, 1/400 dilution (MAB1027; R&D Systems,
Minneapolis, MN, USA); and Foxp3 antibody, 1/100
dilution (ab20034; Abcam, Cambridge, UK). After incu-
bation with the primary antibody, slides were washed in
two changes of PBS before incubation with labeled poly-
mer horseradish peroxidase rabbit/mouse antibody for
15 min (Envision Plus mouse/HRP system; Dako). Sec-
tions were subsequently incubated with Dako-Chromogen
solution and washed in deionized water. Background
staining was performed using Mayers hematoxylin and
sections were then dehydrated through ascending alcohols
to xylene, and mounted. To ensure antibody specificity,
negative control slides were incubated with mouse immu-
noglobulin G1 monoclonal antibody (Abcam). Results of
IHC were evaluated by scanning each slide under low
magnification to identify regions containing positive
immunoreactivity. Immunostaining was further evaluated
at high-power magnification. Tumor samples were exam-
ined by two observers in a blinded manner.
Scoring of B7-H3 Expression
To assess the impact of B7-H3 protein expression by
cancer cells on prognosis, immunohistochemical staining
was performed. Evaluation of B7-H3 staining in cancer
cells was performed semiquantitatively, as described by
Loos et al.10,29 This scoring method is based on the stained
area and intensity of staining. Quantification was made as
follows:\33 % of cancer cells—1; C33 to 66 % of cancer
cells—2; [66 % of cancer cells—3; absent/weak stain-
ing—1; moderately intense staining—2; strong staining—
3. Each section was given a final grade derived as the
product of the area and intensity scores. Sections with a
final score of B3 were classified as showing low B7-H3
expression (B7-H3 low), whereas sections with a final score
[3 were classified as showing high B7-H3 expression (B7-
H3 high).
Scoring of Forkhead Box P3 (Foxp3)-Positive Cells
in Tumor-Infiltrating Lymphocytes (TILs)
Absolute numbers of Foxp3-positive cells in assessable
1-lm invasive tumor cores were counted manually using an
eyepiece reticule without any prior knowledge of specimen
identity. The number of Foxp3-positive cells and tumor-
infiltrating lymphocytes (TILs) was counted using a com-
puterized image analysis system composed of a DP70 CCD
(charge-coupled device) camera (Olympus, Tokyo, Japan)
mounted on an Olympus AX70 light microscope (Olym-
pus). Under 4009 magnification, there were at least 12
independent and intact computerized microscopic fields for
the duplicates of each patient sample. Eight independent
microscopic fields (4009), representing the densest lym-
phocytic infiltrates, were selected for each patient sample to
ensure representativeness and homogeneity. Numbers in the
eight fields were cumulated and then averaged to calculate
the final number for one computerized 4009 microscopic
field (0.0768 mm2/field). The evaluation of Foxp3-positive
cells and TILs was performed by two independent observers
in a blinded manner. Discrepancies in enumeration, within a
range of 5 %, were re-evaluated and a consensus decision
was made. The ratio of Foxp3-positive cells/TILs was cal-
culated for each specimen. We selected the median value as
the cut-off for defining TIL subgroups (median 0.097). High
and low ratios of Foxp3 were termed Foxp3 high and Foxp3
low, respectively.
Statistical Analysis
Actuarial OS and RFS rates were calculated by the
Kaplan–Meier method and analyzed using the log rank test.
Uni- and multivariate analyses were based on the Cox
proportional hazards regression model. Secondary analysis
was performed to assess the relationship between expres-
sion of B7-H3, Foxp3-positive cells and clinicopathological
characteristics. For the comparison of individual variables,
paired-sample t tests, v2 tests and Mann–Whitney U tests
were carried out as appropriate. Two-tailed p \ 0.05 was
judged as significant. All analyses were performed using
Dr. SPSS for Windows, version 12.0 software (SPSS,
Chicago, IL, USA).
RESULTS
B7-H3 Expression of Breast Cancer
B7-H3 protein expression was found in the cytoplasm of
breast tumor cells. Ninety tissue sections from patients with
breast cancer were examined. B7-H3 expression on pri-
mary carcinoma cells was detected at various levels, and
was not detected in seven patients (8 %; Fig. 1a). Weak
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expression was seen in 26 patients (29 %; Fig. 1b), mod-
erate expression in 29 patients (32 %; Fig. 1c), and strong
expression in 28 patients (31 %; Fig. 1d). Depending on
the area of positive immunoactivity, a final overall score
(high or low B7-H3) was established as described in the
‘‘Material and Methods’’ section. A total of 58 % of tumor
samples were identified as B7-H3 high, while 42 %
showed B7-H3 low. No significant associations were
identified between B7-H3 expression and pathological
factors (Table 1).
Foxp3-Positive Cells in TILs of Breast Cancer
Lymphocytes infiltrating within tumors presented in a
diffuse pattern and those in tissue surrounding tumors were
more abundant and tended to form lymphoid aggregates
(Fig. 2). Foxp3 high was observed significantly more often
in tumors with positive nodal status (p \ 0.001), large
tumor size (p \ 0.05), high histological grade (p = 0.002),
or HER2 overexpression (p = 0.001). No significant asso-
ciations were identified between Foxp3-positive cell
infiltration and either ER/PgR expression or lymphovas-
cular invasion (Table 1).
B7-H3 Expression Correlates with Prognosis
B7-H3 high was associated with significantly reduced
RFS in patients with breast cancer [p = 0.0137; hazard
ratio (HR) 0.2781; 95 % confidence interval (CI)
0.1005–0.7696; Fig.3a). Five-year RFS rate of patients
with B7-H3 low was 94.7 % in contrast to 76.3 % in
patients with B7-H3 high. However, OS was not associated
with expression of B7-H3 (p = 0.5660; HR 3.119; 95 % CI
0.5325–18.27; data not shown). Five-year OS rate was 100
and 97.7 % in B7-H3 low and high patients, respectively
(median survival time of B7-H3 high: 89.5 months).
Ratio of Foxp3-Positive Cells in TILs of Breast Cancer
Correlates with Prognosis
Foxp3-positive cell/TIL ratio was associated with RFS
in breast cancer (p = 0.0368; HR 0.2974; 95 % CI
0.09525–0.9286; Fig. 3b). However, Foxp3-positive cell/
TIL ratio did not correlate with OS (p = 0.599; HR 0.5412;
95 % CI 0.055–5.323; data not shown).
Combined Prognosis with Expression of B7-H3
and Foxp3-Positive Cells in TILs
As previously described, B7-H3 expression score did
not correlate with the percentage of Foxp3-positive cells
among TILs, but each value was associated with RFS. We
therefore further categorized patients into four groups: B7-
H3 high/Foxp3 high (n = 24); B7-H3 high/Foxp3 low
(n = 28); B7-H3 low/Foxp3 high (n = 19); and B7-H3
low/Foxp3 low (n = 19) (Fig. 3c). Patients with B7-H3
FIG. 1 Immunohistochemical staining and scoring of B7-H3 in
breast cancer tissue. B7-H3 expression is shown in both cell
membrane and cytoplasm (brown staining). Photos demonstrate each
score’s representative histopathology image. A final score of 1–3
belongs to B7-H3 low, and a final score [3 belongs to B7-H3 high.
a No B7-H3 expression in breast cancer (a final score of 1; B7-H3
low). b Week intensity of staining in[66 % of breast cancer (a final
score of 3; B7-H3 low). c Moderate intensity of staining in[66 % of
breast cancer (a final score of 6; B7-H3 high). d High intensity of
staining in[66 % of breast cancer (a final score of 9; B7-H3 high). e–
h Hematoxylin/eosin staining is shown in a–d. Magnification for all,
940 (scale bar 20 lm)
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high/Foxp3 high relapsed within a shorter period than
patients with B7-H3 low/Foxp3 low (p = 0.001; HR
0.1325; 95 % CI 0.0382–0.4596; Fig. 3c). Interestingly, no
B7-H3 low/Foxp3 low patients showed recurrence. In the
group of B7-H3 low, no significant difference in RFS was
seen between Foxp3 high and low subgroups.
Multivariate Analysis
Multivariate analysis showing HR for patient RFS
conferred by nodal status, tumor size, nuclear grade, higher
numbers of Foxp3-positive TIL and higher expression of
B7-H3. Expression of B7-H3 were revealed as independent
prognostic factors for RFS (p = 0.025; HR 8.5; 95 % CI
1.233–24.269; Table 2).
Correlation between B7-H3 Expression and Tumor-
Infiltrating Foxp3-Positive Cells
No significant difference was found in the percentage of
tumor-infiltrating Foxp3-positive cells between B7-H3
high and B7-H3 low (p = 0.532, Mann–Whitney U test;
Fig.3d).
DISCUSSION
This study demonstrated that the numbers of Foxp3-
positive cells was significantly increased among tumors
with positive nodal status, large tumor size, high histo-
logical grade, and HER2 overexpression. Although B7-H3
has been associated with downregulation and evasion of
host immunity, the clinical and functional significance of
this protein remains unclear. Our study suggested that B7-
H3 expression in breast cancer was unrelated to clinical
and pathological parameters. Patients with B7-H3 high/
Foxp3 high relapsed within a shorter period than patients
with B7-H3 low/Foxp3 low. No significant difference in
terms of RFS was evident between B7-H3 high/Foxp3 high
and B7-H3low/Foxp3 high.
Recent studies of B7 family proteins named B7-H1 (PD-
L1), B7-DC (PD-L2), inducible costimulatory molecule
(ICOSL) and B7-H3 have focused on both tumor immunity
effects and immune evasion. B7-1 and B7-2 are the rep-
resentative proteins of the B7 family and are expressed in
antigen-presenting cells (APCs). However, B7-H1 and B7-
TABLE 1 Correlation of B7-H3 expression in breast cancer cells and Foxp3-positive cells in TILs with clinicopathologic features in 90 patients
Clinical parameters No. of cases Foxp3-positive cell/TIL B7-H3 expression
Low (%) High (%) p valuea Low (%) High (%) p valuea
Age (years)
B50 38 21 (23.3) 17 (18.9) 0.673 12 (13.3) 26 (28.9) 0.641
[50 52 26 (28.9) 26 (28.9) 26 (28.9) 26 (28.9)
Tumor size (cm)
B2 40 28 (31.1) 12 (13.3) 0.003 17 (18.9) 23 (25.6) 1.000
[2 50 19 (21.1) 31 (34.4) 21 (23.3) 29 (32.2)
Nodal metastasis
Without 49 37 (41.1) 21 (13.3) \0.001 23 (25.6) 26 (28.9) 0.393
With 41 10 (11.1) 31 (34.4) 15 (16.7) 26 (28.9)
Hormone receptor
Positive 73 41 (45.6) 32 (35.6) 0.178 28 (31.1) 45 (50.0) 0.173
Negative 17 6 (6.7) 11 (12.2) 10 (11.1) 7 (7.8)
HER2
Positive 40 13 (14.4) 27 (30.0) 0.001 18 (20.0) 22 (24.4) 0.672
Negative 50 34 (37.8) 16 (17.8) 20 (22.2) 30 (33.3)
Nuclear grade
Low (0,1) 34 25 (27.8) 9 (10.0) 0.002 17 (18.9) 17 (18.9) 0.277
High (2,3) 56 22 (24.4) 34 (37.8) 21 (23.3) 35 (38.9)
Vascular invasion
Positive 58 32 (35.6) 26 (28.9) 0.451 24 (26.7) 34 (37.8) 0.828
Negative 32 15 (16.7) 17 (18.9) 14 (15.6) 18 (20.0)
p values less than 0.05 are in bold
Foxp3 forkhead box P3, TILs tumor-infiltrating lymphocytes, HER2 human epidermal growth factor receptor 2
a Chi-square analysis
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H3 are expressed in multiple organs as well as in APCs,
indicating that these molecules potentially act as immune-
modulators at the sites of inflammation.13,30 Human B7-H3
is induced in dendritic cells and monocytes by inflamma-
tory cytokines. B7-H3 binds to an unknown receptor
expressed on activated CD4? and CD8? T cells.14 This
receptor is distinct from CD28, CTLA-4, PD-1 and
ICOS34, the receptors known to bind to other B7 family
proteins. B7-H3 has been reported as a negative regulator
that preferentially downregulates T helper type 1-mediated
immune responses.13 On the other hand, another report
suggests an opposite function, with human B7-H3 aug-
menting TCR-mediated T-cell proliferation, interferon-c
production and generation of cytotoxic T lymphocytes
(CTLs) in vitro, indicating that B7-H3 may have positive
regulatory functions in CTL responses.14
B7-H3 expression has been found in a variety of human
malignancies, including breast, prostate, non-small cell
lung, pancreatic, gastric, endometrial, and colorectal can-
cers.6–8,10,12,17,31–34 It was reported that B7-H3 expression
by breast cancer cells are a potential tumor progression
factor that is a predictor of early regional nodal metastasis.17
In non-small cell lung cancer, Sun et al. 6 suggested B7-
H3 as a factor related to lymph node metastasis. In prostate
cancer, patients with high levels of B7-H3 expression
displayed a worse prognosis than those with low levels of
B7-H3 expression.8 We suspect that the coregulatory
molecule B7-H3 might play a very similar role in breast
cancer. In this study, high expression of B7-H3 was sig-
nificantly associated with shortened RFS in breast cancer.
However, B7-H3 expression did not correlate with any
other clinicopathological factors, such as tumor size, axil-
lary nodal status, ER expression, or HER2 overexpression.
Further identification and understanding of the B7-H3
signaling pathway and potential receptors may offer new
therapeutic strategies for primary breast cancer.
Tregs are present in the tumor microenvironment,
inhibiting autologous T-cell proliferation. Tregs are asso-
ciated with suppression of antitumor immunity. Increasing
numbers of Tregs have been reported in several human
cancers, including not only breast cancer 27 but also lung,35
pancreas,20,36,37 and ovarian tumors.38 Tumor infiltration
by Tregs has been shown to correlate significantly with
worse prognosis among breast cancer patients.27 Foxp3 is a
member of the forkhead box family of transcription factors
and was initially thought to be a master regulatory gene for
lineage commitment or development of CD4?CD25?
Tregs.19 Foxp3 remains the best single marker of Tregs.39
FIG. 2 Immunohistochemical detection of Foxp3-positive cell in
breast carcinoma tissue. Photos demonstrate each group of represen-
tative histopathology image. The ratio of Foxp3-positive cells/TILs
was categorized by median value (median 0.097) into high and low
ratios of Foxp3 (Foxp3 high and low). a Control. b Foxp3 low in
tumor infiltrating lymphocytes (Foxp3-positive cell/TIL; 0.032).
c Foxp3 high in tumor infiltrating lymphocytes (Foxp3-positive
cell/TIL; 0.11). d–f Hematoxylin/eosin staining is shown in a–c.
Magnification for all, 940 (scale bar 20 lm). Foxp3 forkhead box P3,
TILs tumor-infiltrating lymphocytes
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Immunosuppressive Foxp3-positive Tregs have been
linked to poor response to chemotherapy and poor prog-
nosis among breast cancer patients. Decreased peritumoral
Tregs offer an independent predictor of pathological
complete response (pCR), while intratumoral Tregs after
chemotherapy have been associated with both OS and
progression-free survival. Peritumoral Tregs are sensitive
to chemotherapy and associated with pCR, while intratu-
moral Tregs offer an independent prognostic predictor for
breast cancer patients.40
In our results, B7-H3 and Treg expressions were asso-
ciated with poor prognosis among breast cancer patients.
Although no correlations with these expressions were seen,
patients with both B7-H3 high and Treg high showed the
worst prognosis, whereas patients with B7-H3 low and
Treg low showed no recurrence at all. These data suggest
that examination of both B7-H3 and Treg expression may
offer a more accurate prediction of prognosis than the
expression of either molecule alone. We recognized that
these biomarkers are potentially able to be a new thera-
peutic target.
The blockade of B7-H1 known as PD-L1 is under
clinical trials all over the world at the present time. Using
this approach, because B7-H3 has a high homology of B7-
H1, blockade of these molecules is supposed to be of high
feasibility. In addition, downregulation of Treg can be
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FIG. 3 Correlation of RFS with B7-H3 expression in breast cancer
cells and Foxp3-positive cells in TILs. a B7-H3 high (n = 52) was
associated with significantly reduced RFS in patients with breast
cancer (p = 0.0137; HR 0.2781; 95 % CI 0.1005–0.7696). b Patients
with Foxp3 high (n = 43) had significantly improved RFS compared
with Foxp3 low (p = 0.0368; HR 0.2974; 95 % CI 0.0953–0.929).
c Further categorized patients into four groups: B7-H3 high/Foxp3
high; B7-H3 high/Foxp3 low; B7-H3 low/Foxp3 high; and B7-H3
low/Foxp3 low. Patients with B7-H3 high/Foxp3 high relapsed within
a shorter period than patients with B7-H3 low/Foxp3 low
(p = 0.0014; HR 0.1325; 95 % CI 0.0382–0.4596). d The ratio of
Foxp3-positive cells in TILs and B7-H3 protein expression in breast
cancer cells. No significant difference was found in the ratio of tumor-
infiltrating Foxp3-positive cells between B7-H3 high and B7-H3 low
(p = 0.532). This correlation was tested by the Mann–Whitney U test.
RFS recurrence-free survival, Foxp3 forkhead box P3, TILs tumor-
infiltrating lymphocytes, HR hazard ratio, CI confidence interval
TABLE 2 Multivariate analyses showing hazard ratio for patient
RFS conferred by tumor size, nodal status, nuclear grade, vascular
invasion, hormone receptor, HER2, B7-H3 expression, Foxp3-posi-
tive cell in TILs
Variable Hazard
ratio
95 % CI p valuea
B7-H3 expression (high vs. low) 5.471 1.233–24.269 0.025






Tumor size (B2 vs. [2 cm) 1.798 0.449–7.199 0.407
Nodal status (?ve vs. –ve) 1.588 0.468–5.390 0.458
Nuclear grade (grade 1 vs. grade
2,3)
0.669 0.105–4.259 0.671
Hormone receptor (?ve vs. –ve) 0.779 0.192–3.161 0.726
HER2 (?ve vs. –ve) 1.070 0.351–3.260 0.905
RFS recurrence-free survival, HER2 human epidermal growth factor
receptor 2, Foxp3 forkhead box P3, TILs tumor-infiltrating lympho-
cytes, ?ve positive, –ve negative, CI confidence interval
a Cox’s proportional hazards regression analysis
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studies have demonstrated that patients with ER/PgR-
positive cancer frequently relapsed with non-visceral dis-
ease. Most patients could, for a time, be controlled for
treatment by endocrine therapy. In this study, 73 patients
(81 %) had ER positive tumors. Therefore, there were no
significant differentiations between these expressions and
OS. Many analyses showed that breast cancer subtypes
were associated with the prognosis, and ER-positive
patients relapsed 5 years after initial therapy.42,43 In this
study, the median follow-up duration was 67 months.
Although this period is no longer of great significance, we
consider that it is not too short in assessing the prognosis.
CONCLUSIONS
This study showed that detection of B7-H3 on breast
cancer and Tregs among infiltrating T cells predicts
worsened prognosis. Even in slow-growth-type cancers
such as breast cancer, tumor immune evasion through B7-
H3 expression on tumor cells and/or Treg infiltration acts
as an important factor in determining prognosis.
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